Ítem
Acceso Abierto

Eficacia de la melatonina en insomnio primario en el adulto mayor: revisión sistemática de la literatura

Mostrar el registro sencillo de la publicación
dc.contributor.advisorMorón Duarte, Lina Sofía
dc.contributor.advisorRendón Quintero, Mauricio Eduardo
dc.creatorGaitán Quintero, Lina María
dc.creatorRondón Rueda, Paola Andrea
dc.creator.degreeEspecialista en Psiquiatría
dc.date.accessioned2015-03-25T17:06:21Z
dc.date.available2015-03-25T17:06:21Z
dc.date.created2015-03-04
dc.date.issued2015
dc.descriptionIntroducción: La melatonina, una sustancia cronobiótica endógena, es cada vez más empleada para el manejo de los problemas del sueño en adultos mayores por su aparente eficacia y buen perfil de eventos adversos. En este sentido, se intentó evaluar la eficacia de la melatonina en el tratamiento del insomnio primario en el adulto mayor (≥55 años) comparado con benzodiacepinas, zopiclona y placebo a la luz de la evidencia disponible en los últimos cinco años. Métodos: Revisión sistemática de la literatura. Resultados: En comparación con placebo, al parecer la melatonina mejora la calidad y los hábitos de sueño, no así la latencia de inicio de sueño en mediciones subjetivas ni objetivas (polisomnografía); a diferencia de otros medicamentos hipnóticos, no altera la arquitectura del sueño ni genera síntomas diurnos. Conclusiones: No se encontró evidencia que soporte el uso de melatonina en adultos mayores de 55 años para la reducción de la latencia de sueño, aumento del tiempo total de sueño, mejoría de la eficiencia del sueño, disminución de despertares nocturnos o mejoría de la calidad de sueño. Es necesario adelantar más estudios en comparación con placebo y otros medicamentos.spa
dc.description.abstractIntroduction: Melatonin, an endogenous chronobiotic substance, is increasingly used for the management of sleep problems in older adults because of their apparent efficacy and safety. Here, we aimed to assess the effectiveness of melatonin in the treatment of primary insomnia in the elderly (≥55 years) compared with benzodiazepines, zopiclone and placebo accordingto available evidence in past five years. Methods: Systematic review of the literature. Results: Compared with placebo, apparently melatonin improves the quality and sleeping habits, not the sleep onset latency on subjective or objective measures (polysomnography); unlike other hypnotic drugs, Melatonin does not alter sleep architecture or generate daytime symptoms. Conclusions: No evidence was found to support the use of melatonin in adults over 55 years to reduce sleep latency, increased total sleep time, improved sleep efficiency, decreased nocturnal awakenings or improving quality sleep. Further study is necessary to advance comparing melatonin treatment to placebo and other medications.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_10303
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/10303
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de Medicinaspa
dc.publisher.programEspecialización en Psiquiatríaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto completo)spa
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.source.bibliographicCitationOrganización Panamericana de la Salud. Estrategias y plan de acción sobre la Salud mental. Washington EUA: 49 Consejo Directivo; 2.009.
dc.source.bibliographicCitationOrganización Mundial de la Salud. MHGap: Mejora y Ampliación de la atención de los trastornos mentales, neurológicos y por abusos de sustancias. [en línea]. VersiónProvisional. 2008. http://www.who.int/mentalhealth/mhgap/mhg apspanish.pdf
dc.source.bibliographicCitationOrganización Panamericana de la Salud. Convención Interamericana para la eliminación de todas las formas de discriminación contra las personas con discapacidad. Washington EUA: A.G Res. 1608; 1.999.
dc.source.bibliographicCitationMinisterio de la Protección Social. Estudio Nacional de Salud Mental en Colombia. Fundación FES Social 2003. [en línea] Colombia 2005. http://www.minproteccionsocial.gov.co/Documentos%20y%20Publicaciones/ESTUDIO%20NACIONAL%20DE%20SALUD%20MENTAL %20EN% 20COLOMBIA.pdf.
dc.source.bibliographicCitationVera D, Rubiano S. Revisión de lineamientos y estrategias en salud mental en Colombia y Chile. Bogotá: Departamento de Salud Pública, Medicina, Universidad Nacional; 2.012.
dc.source.bibliographicCitationWalsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22(Suppl. 2):S386–93.
dc.source.bibliographicCitationBuscemi N, Vandermeer B, Hooton N, Baker G, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ. 2006; 332(7538): 385–393.
dc.source.bibliographicCitationLiu J, Wang L. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int J Clin Pract, September 2012; 66, 9, 867–873.
dc.source.bibliographicCitationOhayon MM, Zulley J, Guilleminault C et al. How age and daytime activities are related to insomnia in the general population: consequences for older people. J Am Geriatr Soc 2001; 49: 360–6.
dc.source.bibliographicCitationMontgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003; Issue 1: CD003161.
dc.source.bibliographicCitationKuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Medicine 2014; 15: 385–392
dc.source.bibliographicCitationRoth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3:S7–S10.
dc.source.bibliographicCitationTroxel WM, Buysse DJ, Matthews KA, Kip KE, Strollo PJ, Hall M, et al. Sleep symptoms predict the development of the metabolic syndrome. Sleep 2010;33:1633–40.
dc.source.bibliographicCitationLaugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation 2011;124:2073–81.
dc.source.bibliographicCitationVgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep 2009;32:491–7.
dc.source.bibliographicCitationBaglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord 2011;135:10–9.
dc.source.bibliographicCitationBrower KJ. Insomnia, alcoholism and relapse. Sleep Med Rev 2003;7:523–39.
dc.source.bibliographicCitationWalsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22(Suppl. 2):S386–93.
dc.source.bibliographicCitationMorgan K, Kucharczyk E, Gregory P. Insomnia: evidence-based approaches to assessment and management. Clin Med 2.011; 11: 278–281.
dc.source.bibliographicCitationFerracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLoS ONE 2.013; 8(5): e63773.
dc.source.bibliographicCitationSmith MT, Perlis ML, Park A, Smith MS, Pennington J, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2.002; 159: 5–11.
dc.source.bibliographicCitationSrinivasan V, Brzezinski A, Pandi-Perumal SR, Spence DW, Cardinali DP. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuro psychopharmacol Biol Psychiatry 2.011; 35: 913–923.
dc.source.bibliographicCitationSingh M, Jadhav HR. Melatonin: functions and ligands. Drug Discovery Today 2.014: Volume 00, Number 00.
dc.source.bibliographicCitationZagajewski, J. et al. Conversion of L-tryptophan to melatonin in the GIT: new HPLC method enabling simultaneous determination of six metabolites of L-tryptophan by native fluorescence and UV–VIS detection. J. Phys. Pharmacol 2.012. 63, 613–621.
dc.source.bibliographicCitationLerner, A.B. et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J. Am. Chem. Soc 1.958; 80, 2587–2592.
dc.source.bibliographicCitationBliwise DL, Ansari FP. Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey. Sleep 2.007; 30: 881–884.
dc.source.bibliographicCitationhttp://www.who.int/world-health-day/2012/toolkit/background/es/
dc.source.bibliographicCitationKamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. Am J Med. 2006 Jun;119(6):463-9.
dc.source.bibliographicCitationVallejo J. Tratado de Psiquiatría. Marbán. 2013
dc.source.bibliographicCitationCrowley K. Sleep and sleep disorders in older adults. Neuropsychol Rev. 2011 Mar;21(1):41-53.
dc.source.bibliographicCitationBellon A. Searching for new options for treating insomnia: are melatonin andramelteon beneficial?.J Psychiatr Pract. 2006 Jul;12(4):229-43.
dc.source.bibliographicCitationOlde Rikkert MG, Rigaud AS. Melatonin in elderly patients with insomnia. A systematic review. Z Gerontol Geriatr. 2001 Dec;34(6):491-7.
dc.source.bibliographicCitationSpiegel K, Tasali E, Penev P, et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141:846-850.
dc.source.bibliographicCitationMeier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol. 2004;43:678-683.
dc.source.bibliographicCitationSalzman C. Pharmacologic Treatment of Disturbed Sleep in the Elderly Review. Harv Rev Psychiatry. 2008. Vol 16. 271-278.
dc.source.bibliographicCitation.Vissers FH, Knipschild PG, Crebolder HF. Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. . Pharm World Sci. 2007 Dec;29(6):641-6.
dc.source.bibliographicCitationMorin CH, Bastien CH, BrinkD, Brown TR. Adverse effects of temazepam in older adults with chronic insomnia. Hum Psychopharmacol 2003; 18: 75-82.
dc.source.bibliographicCitationLyseng-Williamson KA. Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years. Drugs Aging. 2012 Nov;29(11):911-23.
dc.source.bibliographicCitationHedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. Int J Geriatr Psynt J Geriatr Psychiatry 2000; 15: 704-12.
dc.source.bibliographicCitationCheng-Fang Y. Correlates of Dependence and Beliefs About the Use of Hypnotics Among Zolpidem and Zopiclone Users. Subst Use Misuse, 50: 350-357, 2015.
dc.source.bibliographicCitationZammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91.
dc.source.bibliographicCitationHaria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs & Aging. 1994;4:331-355.
dc.source.bibliographicCitationCardinali DP, Srinivasan V, Brzezinski A. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52(4): 365–75.
dc.source.bibliographicCitationWilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577–601.
dc.source.bibliographicCitationCircadin 2 mg prolonged-release tablets: summary of product characteristics. London: European Medicines Agency; 2012.
dc.source.bibliographicCitationLemoine P, Garfinkel D, Laudon M, et al. Prolonged-release melatonin for insomnia: an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. 2011;7: 301–11.
dc.source.bibliographicCitationJames SP, Sack DA, Rosenthal NE. Melatonin administration and insomnia. Neuropsychopharmacology 1990;3:19–23.
dc.source.bibliographicCitationMacFarlane JG, Cleghorn JM, Brown mg, et al. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: A preliminary study. Biol Psychiatry 1991;30:371–6.
dc.source.bibliographicCitationHaimov I, Peretz L, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598–603.
dc.source.bibliographicCitationGarfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995;346:541–4.
dc.source.bibliographicCitationEllis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res 1996;5:61–5.
dc.source.bibliographicCitationHughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: Assessment in a clinical trial of melatonin replacement. Sleep 1998;21:52–68.
dc.source.bibliographicCitationJean-Louis G, von Gizycki H, Zizi F.Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. PinealRes1.998; 25:177–183
dc.source.bibliographicCitationZhdanova IV,Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001;86:4727–30.
dc.source.bibliographicCitationBaskett JJ, Broad JB,Wood PC, et al. Does melatonin improve sleep in older people? A randomized crossover trial. Age and Ageing 2003;32:164–70.
dc.source.bibliographicCitationAlmeida Montes LG, Ontiveros Uribe MP, Cortes Sotres J, et al. Treatment of primary insomnia with melatonin: A doubleblind, placebo-controlled, crossover study. J Psychiatry Neurosci 2003;28:191–6.
dc.source.bibliographicCitationGarfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin. A new clinical appraoch. Arch Intern Med 1999;159:2456–60.
dc.source.bibliographicCitationCardinali DP, Gvozdenovich E, Kaplan MR, Fainstein I, Shifis HA, Perez Lloret S, Albornoz L, Negri A. A double blind-placebo controlled study on melatonin to reduce anxiolytic benzodiazepine use in the elderly. Neuro Endocrin Lett 2002;23(1):55–60.
dc.source.bibliographicCitationKunz D, Bineau S, Maman K, et al. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother. 2012;13(1):9–16.
dc.source.bibliographicCitationSinger C, Tractenberg RE, Kaye J, et al. A multicenter, placebo- controlled trial of melatonin for sleep disturbance inAlzheimer’s disease. Sleep 2003;26:893–901.
dc.source.bibliographicCitationSerfaty M, Kennell-Webb S,Warner J, et al. Double blind randomized placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry 2002; 17:1120–7.
dc.source.bibliographicCitationGschliesser V, Frauscher B Bradauer E et al. PLM detection By acthigraphy compared to polisomnography : a validation and comparison of two actigraphs. Sleep Med. 2009 Mar;10(3):306-11.
dc.source.bibliographicCitationBrzezinski A, Vangel MG, Wurtmann RJ et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50.
dc.source.bibliographicCitationBuscemi N, Vandermeer B, Hooton N et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: A metaanalysis. J Gen Intern Med 2005; 20: 1151-8
dc.source.bibliographicCitationBuscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. (2007). The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 22:1335–1350
dc.source.bibliographicCitationOtmani S, Demazieres A, Staner C, Jacob N, Nir T, Zisapel N, Staner L (2008). Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 23:693–705
dc.source.bibliographicCitationLittner M, Hirshkowitz M, Kramer M, Kapen S, Anderson WM, Bailey D, Berry RB, Davila D, Johnson S, Kushida C, et al: Practice parameters for using polysomnography to evaluate insomnia: an update. Sleep 2003, 26(6):754-760.
dc.source.bibliographicCitationBrzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I. (2005). Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41–50
dc.source.bibliographicCitationPaul MA, Gray G, Kenny G, Pigeau RA (2003). Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med 74:1263–1270.
dc.source.bibliographicCitationSHARMA, M., et al. Circadian rhythms of melatonin and cortisol in aging. Biological psychiatry, 1989, vol. 25, no 3, p. 305-319.)
dc.source.bibliographicCitationKunz D, Schmitz S, Mahlberg R, et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology 1999;21:765-72
dc.source.bibliographicCitationZhdanova IV. Comment on ‘Melatonin as a hypnotic: con’. Sleep Med Rev 2005;9:81; discussion 83-4 21. Mahlberg R, Kienast T, Hadel S, et al. Degree of pineal calcification (DOC) is associated with polysomnographic sleep measures in primary insomnia patients. Sleep Med 2009;10:439-45
dc.source.bibliographicCitationZisapel N, Tarrasch R, Laudon M: The relationship between melatonin and cortisol rhythms: clinical implications of melatonin therapy. Drug Dev Res 2005, 65(3):119-125.
dc.source.bibliographicCitationLemoine P, Wade AG, Katz A, Nir T, Zisapel N. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Int Blood PRess Control 2012; 5: 9-17
dc.source.bibliographicCitationWU, Ying-Hui, et al. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiology of aging, 2007, vol. 28, no 8, p. 1239-1247.)
dc.source.bibliographicCitationKunz D, Bineau S, Maman K, Milea D, Toumi M. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother. 2012 Jan;13(1):9-16.)
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectMelatoninaspa
dc.subjectadulto mayorspa
dc.subjectinsomnio primario.spa
dc.subject.ddcEnfermedades
dc.subject.decsPsiquiatríaspa
dc.subject.decsMelatoninaspa
dc.subject.decsInsomniospa
dc.subject.decsNarcóticosspa
dc.subject.decsNeurologíaspa
dc.subject.keywordMelatonineng
dc.subject.keywordelderlyeng
dc.subject.keywordinsomnia.eng
dc.titleEficacia de la melatonina en insomnio primario en el adulto mayor: revisión sistemática de la literaturaspa
dc.typemasterThesiseng
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de gradospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
GaitanQuintero-LinaMaria-2015.pdf
Tamaño:
1.52 MB
Formato:
Adobe Portable Document Format
Descripción:
Artículo principal
Descargar
Colecciones
Especialización en Psiquiatría